Skip to main content
Clinical Trials/CTRI/2018/06/014439
CTRI/2018/06/014439Active, not recruitingPhase 4

An Open Labeled, Placebo Controlled Trial to Evaluate Role of Probiotic- Bacillus subtilis HU58 and Bacillus coagulans SC208 on Antibiotic associated Diarrhoea in Humans

Synergia Life Sciences Pvt Ltd1 site in 1 country75 target enrollmentStarted: June 18, 2018Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Active, not recruiting
Enrollment
75
Locations
1
Primary Endpoint
To evaluate the role of Probiotic- Bacillus subtilis HU58 and Bacillus coagulans SC208 in Antibiotic associated Diarrhoea in Humans in comparison to placebo

Study Overview

Brief Summary

The current study is formulated in order to evaluate the effect of supplementation of Probiotic Bacillus subtilis HU58 and Bacillus coagulans SC209 on Antibiotic associated Diarrhea in humans in comparison with placebo.

N = 75

Study Design

Study Type
Interventional
Allocation
Not Applicable
Masking
Open Label

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1.Male and female aged 18 to
  • •2.Stable ECG.
  • •3.Willing to give informed consent.

Exclusion Criteria

  • •1.Sero positive patients.
  • •2.Pregnancy.
  • •3.Subjects who are on other Probiotics or prebiotics.
  • •4.Subjects who are addicted to tobacco, alcohol.
  • •5.Subjects who are on any other medication than prescribed oral antibiotics.

Outcomes

Primary Outcomes

To evaluate the role of Probiotic- Bacillus subtilis HU58 and Bacillus coagulans SC208 in Antibiotic associated Diarrhoea in Humans in comparison to placebo

Time Frame: 15 days

Secondary Outcomes

  • Safety and tolerability; clinical variables(15 days)

Investigators

Sponsor Class
Pharmaceutical industry-Indian

Study Sites (1)

Loading locations...

Similar Trials

To study the effect of Probiotics Bacillus... | Clinical Trial